NCTN: Randomized Phase III Trial of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer (CALGB-40601)
Study ID: CALGB-40601
NCT Number: NCT00770809
Alliance for Clinical Trials in Oncology
Submitted in collaboration with the NCTN/NCORP Data Archive
Trial Title: NCTN: Randomized Phase III Trial of Paclitaxel + Trastuzumab + Lapatinib versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer (CALGB-40601)
Trial Description: This randomized phase III trial studies paclitaxel and trastuzumab with or without lapatinib to see how well they work in treating patients with stage II or stage III breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel with trastuzumab and/or lapatinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known which regimen is more effective in treating patients with breast cancer.
Clinical data presented in the following publication(s):
Disease type(s): Breast Neoplasm - Breast Cancer - Invasive
Clinical dataset(s) included:
- NCT00770809-D1 (PMID 26527775): Dataset NCT00770809-D1 is one of 7 datasets (-D1 through -D7) associated with PubMed ID 26527775, CALGB-40601's primary publication. This dataset contains information for the treatment consort diagram, including treatment arm and reason for treatment discontinuation, and evaluability of patients for the efficacy analysis.
- NCT00770809-D2 (PMID 26527775): Dataset NCT00770809-D2 is one of 7 datasets (-D1 through -D7) associated with PubMed ID 26527775, CALGB-40601's primary publication. This dataset contains information for the Genomic analysis section of the consort diagram (including the patients used in the pre-Rx and pre- v post-Rx genomic analysis). This data set includes the n=295 patients evaluable for efficacy.
- NCT00770809-D3 (PMID 26527775): Dataset NCT00770809-D3 is one of 7 datasets (-D1 through -D7) associated with PubMed ID 26527775, CALGB-40601's primary publication. This dataset contains information for the baseline characteristics, including hormone receptor status. It also includes the pathologic complete response status (pCR) for all patients included in the efficacy analysis. Both the pCR evaluated with breast-only and with axillary node criteria are included here.
- NCT00770809-D4 (PMID 26527775): Dataset NCT00770809-D4 is one of 7 datasets (-D1 through -D7) associated with PubMed ID 26527775, CALGB-40601's primary publication. This dataset contains information for Figure 3. It includes information on receptor status, intrinsic subtype, PIK3CA mutation status, pre- and post-treatment gene expression data, and pathologic complete response.
- NCT00770809-D5 (PMID 26527775): Dataset NCT00770809-D5 is one of 7 datasets (-D1 through -D7) associated with PubMed ID 26527775, CALGB-40601's primary publication. This dataset contains information on all the treatment delays reported for each of the three drugs.
- NCT00770809-D6 (PMID 26527775): Dataset NCT00770809-D6 is one of 7 datasets (-D1 through -D7) associated with PubMed ID 26527775, CALGB-40601's primary publication. This dataset contains information on all the adverse events reported during each cycle while on trial. Therefore, patients can report the same adverse event over multiple courses of treatment.
- NCT00770809-D7 (PMID 26527775): Dataset NCT00770809-D7 is one of 7 datasets (-D1 through -D7) associated with PubMed ID 26527775, CALGB-40601's primary publication. This dataset contains information for the gene expression and gene signature portion of the analysis.
- NCT00770809-D8 (PMID 33095682): Dataset NCT00770809-D8 is associated with PubMed ID 33095682, reporting on relapse-free survival and overall survival from CALGB-40601. This dataset contains intrinsic subtype, baseline characteristics, treatment information, and survival data presented in the publication. RNAseq data has been submitted to GEO (Gene Expression Omnibus; GSE116335).
Additional proteogenomic data are available for this trial under phs003576.
Additional genomic and transcriptomic data are available for this trial under phs001570.
You are encouraged to view the PDF data dictionaries found in the “Documents” tab of the dbGaP study page, which may contain additional information regarding the data or the associated publication(s).
- Type: Interventional
- Archive: The database of Genotypes and Phenotypes (dbGaP)
